NRx Pharmaceuticals Expands Access to Investigational Ketamine Therapy for Suicidal Depression

NRx Pharmaceuticals Expands Access to Investigational Ketamine Therapy for Suicidal Depression

WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that it will make its investigational therapy NRX-100, a preservative-free formulation of ketamine, available through the U.S. Food and Drug Administration’s expanded access program. The move follows the FDA’s decision to grant Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. Addressing an Urgent …

NRx Pharmaceuticals Announces Expanded Access Policy for NRX-100

Open the article to view the coverage from citybiz

New Expanded Access Policy for NRX-100 for Suicidal Ideation

NRX-100, a preservative-free ketamine, announces expanded access policy for treatment of suicidal ideation in depression, offering new hope for patients.